Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TARIS Biomedical

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

- PMLiVE

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma

- PMLiVE

Johnson & Johnson offers $8.9bn to resolve all talcum powder lawsuits

The company faces more than 38,000 lawsuits alleging that its talc products cause cancer

- PMLiVE

Johnson & Johnson’s strategy to resolve talcum powder lawsuits blocked by US appeals court

The company faces more than 38,000 lawsuits alleging that its talc products contain asbestos

- PMLiVE

BMS reports positive three-year results for Opdivo to treat bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

- PMLiVE

Johnson & Johnson to acquire Abiomed in deal worth $16.6bn

The agreement will broaden the company’s cardiovascular technologies portfolio

Modern Medical Affairs: How to Leverage Tech and Data as an MSL

Dr. Luca Dezzani, VP of US Oncology Medical Affairs at Johnson & Johnson, explores innovation in Medical Affairs, new technologies for data dissemination and medical education, how to engage with...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links